Ophthalmic composition containing sulfasalazine and hyaluronic acid

A technology for sulfasalazine and ophthalmic compositions, applied in the field of ophthalmic compositions, can solve the problems of increasing the process of forming salts, increasing the cost, complicating the preparation process, etc., and achieving the effects of improving solubility and improving stability

Pending Publication Date: 2019-09-13
KUKJE PHARMA IND CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the problem with this technology is that it needs to add a process of forming a salt or a PEGylation process, which complicates the preparation process and increases the cost

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic composition containing sulfasalazine and hyaluronic acid
  • Ophthalmic composition containing sulfasalazine and hyaluronic acid
  • Ophthalmic composition containing sulfasalazine and hyaluronic acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] [Example 1] Preparation of composition in borax / boric acid buffer

[0026] A borax / boric acid buffer was used to prepare the compositions shown in Table 1 below, which contained Myrj S40, Cremophor EL or Tween 80 as surfactants.

[0027] [Table 1] Compositions prepared in borax / boric acid buffer

[0028]

Embodiment 2

[0029] [Example 2] Preparation of composition in citrate buffer

[0030] The compositions shown in Table 2 below were prepared using citrate buffer containing Myrj S40, Cremophor EL or Tween 80 as surfactants.

[0031] [Table 2] Compositions prepared in citrate buffer

[0032]

Embodiment 3

[0033] [Example 3] Preparation of composition in trometamol (trometamol) buffer

[0034] The compositions shown in Table 3 below were prepared using trometamol buffer containing Myrj S40, CremophorEL or Tween 80 as surfactants.

[0035] [Table 3] Compositions prepared in tromethamine buffer

[0036]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An ophthalmic composition containing sulfasalazine and hyaluronic acid is disclosed.

Description

technical field [0001] The present invention relates to an ophthalmic composition containing sulfasalazine or a salt thereof and hyaluronic acid or a salt thereof. Background technique [0002] Sulfasalazine, having a structure represented by the following formula 1, is a non-steroidal anti-inflammatory drug which is used to treat colitis and enteritis, and is known to be effective also in the treatment of eye diseases such as retinal damage (see Korean Patent Application Publication No. 2003-0023098): [0003] [Formula 1] [0004] [0005] In addition, a mixture of sulfasalazine and hyaluronic acid (HA) is known to be effective in treating eye diseases such as cataract and dry eye (see Korean Patent Application Publication No. 2008-0092631). [0006] Sulfasalazine is practically insoluble in water (solubility: 0.0464 mg / ml). This solubility characteristic of sulfasalazine is a barrier to formulating sulfasalazine as a liquid ophthalmic composition for the treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/635A61K31/728A61K9/00A61K9/08
CPCA61K9/08A61K31/635A61K31/728A61K9/0048A61K47/14A61P27/02A61P27/04A61P27/12A61K2300/00A61K47/34
Inventor 裵贤柱金承基金范中李周姬金永官
Owner KUKJE PHARMA IND CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap